Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
62,963.32 +3,654.57 (+6.16%) CMC Crypto 200
1,357.44 +80.46 (+6.30%)
Crinetics Pharmaceuticals, Inc. (CRNX)
After hours:
| Previous close | 46.78 |
| Open | 47.52 |
| Bid | 47.13 x 200 |
| Ask | 47.23 x 200 |
| Day's range | 47.13 - 48.37 |
| 52-week range | 15.76 - 49.58 |
| Volume | |
| Avg. volume | 811,159 |
| Market cap | 3.717B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.69 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 57.92 |
GlobeNewswireCrinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 9th @ 4:30 PM ETDomestic:1-888-886-7786International:1-416-764-8658Conference ID: 71864759 Participa
- GlobeNewswire
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its common stock to ten new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements m
GuruFocus.comInsider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)
Jeff Knight, the Chief Operating Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), has sold 32,359 shares of the company on March 22, 2024, according to a recent SEC filing.
